These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29297274)

  • 1. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
    Sharifi M; Buzatu D; Harris S; Wilkes J
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias.
    Sharifi M
    J Mol Graph Model; 2017 Sep; 76():152-160. PubMed ID: 28756335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
    Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
    Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes.
    Lazzerini PE; Yue Y; Srivastava U; Fabris F; Capecchi PL; Bertolozzi I; Bacarelli MR; Morozzi G; Acampa M; Natale M; El-Sherif N; Galeazzi M; Laghi-Pasini F; Boutjdir M
    Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003419. PubMed ID: 27030700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
    Testai L; Bianucci AM; Massarelli I; Breschi MC; Martinotti E; Calderone V
    Curr Med Chem; 2004 Oct; 11(20):2691-706. PubMed ID: 15544470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MICE models: superior to the HERG model in predicting Torsade de Pointes.
    Kramer J; Obejero-Paz CA; Myatt G; Kuryshev YA; Bruening-Wright A; Verducci JS; Brown AM
    Sci Rep; 2013; 3():2100. PubMed ID: 23812503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias.
    Yang PC; Perissinotti LL; López-Redondo F; Wang Y; DeMarco KR; Jeng MT; Vorobyov I; Harvey RD; Kurokawa J; Noskov SY; Clancy CE
    J Physiol; 2017 Jul; 595(14):4695-4723. PubMed ID: 28516454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P; Warner B
    J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting the hERG safety margin after 20 years of routine hERG screening.
    Leishman DJ; Abernathy MM; Wang EB
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.
    Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA
    Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular mechanisms of Torsade de Pointes.
    Poelzing S; Rosenbaum DS
    Novartis Found Symp; 2005; 266():204-17; discussion 217-24. PubMed ID: 16050270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.